SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 584.80 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 61.80K shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 523.00K shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 121.80K shares, a 193.32% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 29.68K shares, a 1003.08% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 154.28K shares, a 38.04% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 248.98K shares, a 319.52% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 59.35K shares, a 93.06% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 855.01K shares, a 160.10% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 61.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 584.80K shares 10-Q · filed 2026-08-06 | 706.59K shares derived: sum of 3 quarters · filed 2026-08-06 | 736.28K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 523.00K shares 10-Q · filed 2026-05-12 | 644.79K shares derived: sum of 2 quarters · filed 2026-05-12 | 674.48K shares derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-12-31 | 121.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 151.48K shares derived: sum of 2 quarters · filed 2026-03-09 | 154.28K shares 10-K · filed 2026-03-09 | |
| 2025-09-30 | 29.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 32.48K shares 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | 2.80K shares 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | 41.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 44.21K shares derived: sum of 2 quarters · filed 2025-03-31 | 247.73K shares derived: sum of 3 quarters · filed 2025-03-31 | 248.98K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 2.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 206.21K shares derived: sum of 2 quarters · filed 2024-11-06 | 207.46K shares 10-Q · filed 2024-11-06 | 226.40K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 203.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 204.77K shares 10-Q · filed 2024-08-08 | 223.71K shares derived: sum of 3 quarters · filed 2024-08-08 | 230.27K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.25K shares 10-Q · filed 2024-05-20 | 20.19K shares derived: sum of 2 quarters · filed 2024-05-20 | 26.75K shares derived: sum of 3 quarters · filed 2024-05-20 | 46.63K shares derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-12-31 | 18.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 25.50K shares derived: sum of 2 quarters · filed 2024-03-29 | 45.39K shares derived: sum of 3 quarters · filed 2024-03-29 | 59.35K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 6.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 26.45K shares derived: sum of 2 quarters · filed 2023-11-13 | 40.41K shares 10-Q · filed 2023-11-13 | 392.14K shares derived: sum of 4 quarters · filed 2023-11-13 |
| 2023-06-30 | 19.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 33.85K shares 10-Q · filed 2023-08-21 | 385.58K shares derived: sum of 3 quarters · filed 2023-08-21 | 632.38K shares derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | 13.96K shares 10-Q · filed 2023-05-15 | 365.70K shares derived: sum of 2 quarters · filed 2023-05-15 | 612.50K shares derived: sum of 3 quarters · filed 2023-05-15 | 844.26K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 351.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | 598.53K shares derived: sum of 2 quarters · filed 2023-04-14 | 830.29K shares derived: sum of 3 quarters · filed 2023-04-14 | 855.01K shares 10-K · filed 2023-04-14 |
| 2022-09-30 | 246.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 478.56K shares derived: sum of 2 quarters · filed 2022-11-14 | 503.27K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 231.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 256.48K shares 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 24.71K shares 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 328.72K shares 10-K/A · filed 2023-04-28 | |||
| 2020-12-31 | 0.00 shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |